The Goldman Sachs Group Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00

The Goldman Sachs Group has recently lowered its price target for Gossamer Bio (NASDAQGOSS) from $12.00 to $8.00. This means that the investment bank now believes that the stock is undervalued and has the potential for growth, but not as much as previously thought.

Gossamer Bio is a biotechnology company that specializes in developing and commercializing gene therapies for rare genetic diseases. The company's flagship product, Zolgensma, is a gene therapy for spinal muscular atrophy (SMA), which is a rare and debilitating muscle disease.

In recent years, Gossamer Bio has made significant progress in developing and testing its gene therapies, including Zolgensma, which was approved by the US Food and Drug Administration (FDA) in May 2019. The company has also announced plans to expand its pipeline of gene therapies for other rare genetic diseases.

Despite this progress, Gossamer Bio's stock price has been volatile, with significant fluctuations in value over the past year. The lowering of the Goldman Sachs Group's price target reflects the investment bank's revised assessment of the company's potential for growth and profitability.

It is important to note that this information is based on publicly available data and should not be considered financial advice. Investors should always conduct their own research and consult with a financial advisor before making any investment decisions.